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L IVER transplantation is a form of therapy that pro-
vides a new life to patients with advanced and 
otherwise lethal liver disease. I·' Like all advanced tech-
nologies. it is expensive.8 .9 Costs vary considerably and 
reflect the effects of a wide range of variables. A major 
factor in terms of cost. however. is the length of hospital-
ization required following the initial surgical procedure. 
This variable can be easily measured. In an effort to 
determine the effect of the type of immunosuppression 
used on liver transplant costs. the following study was 
performed. 
METHODS 
Subjects 
Twenty patients who received a primary liver graft at the Presb~­
terian-L'niversity Hospital under FK 506 immunotherapy "ere 
matched with 20 patients who received a primary liver graft at the 
same institution" ithin the preceding 2 years under C) A immu· 
notherapy. Each patient" ho undef" ent tran'iplantation and re-
ceived FK 506 therapy \\ a, matched for age. gender. primdry li\ er 
di~ea.,e. and L'nited "et\\ork for Organ Sharing (L'"OS I ''::L'r~ 
with one of the patienh "ho received CyA as the primar\ 
immuno,uppre"ant. 
Cost Analysis 
The hospital charges accrued by each patient from time ,)f 
transplantation to initial discharge were compared. These "ere 
further segregated into costs for types of individual services to 
determine where differences between groups might have L)C-
curred. 
Statistical Analysis 
All data are reported as mean values :': SE~1. Statistical anal~ ,is 
was performed using a two-tailed Student's I test. P < 0.05 was 
considered to be significant. 
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Table 1. Characteristics of the Two Groups of Subjects Studied 
Age :' 
FK 506·Treateo L ... er Disease UNOS C,A,:·e.;·e-:: 
Pallenls Sex Age C) lagnos'5 Score Pal'e-'; 
1 M 31 PSC 2 35 
2 M 18 Alagille 5 syndrome 1 18 
3 M 38 PNC-NANB 3 35 
4 M 19 PSC 3 2E 
5 \1 43 PNC-C ~: 
6 M 38 PNC-"'ANB 4 .!: 
7 M 42 PNC-ETOH 1 4c 
8 M 39 PNC-ETOH 4 ~'-
9 F 41 PNC-B 2 36 
10 F 49 Budc·CriarJ syndror"1e 4 25 
11 M 49 PSC 2 4: 
12 M 28 Carolis cisease 2 24 
13 F 41 PBC 2 44 
14 F 55 PBC 2 "~ 
15 F 37 PNC-ETOH 3 33 
16 M 55 PNC-ETOH 3 58 
17 M 41 PNC-ETOH 3 44 
18 F 33 PBC 1 42 
19 F 64 PNC-C 2 64 
20 F 43 PNC-ETOH 2 4" 
Mean:: SEM 402 "- 2 5 2 5 "- 0 2 40.1 = 26 
Abbreviaiions PSC. primary sclerOSing chOlangitis. PNC-NANB Pos!-".ecrc!: : ''hOSIS due to putative NANB. PNC-C. cryptogenic post·necrot,c CirrhOSIS PNC-E-::;'" 
alcoholiC CirrhOSIS. PNC-B Dos:·necrotIC C,'rhOSIS due 10 "epatll,s B , -.s PS: :'."ary biliary CirrhOSIS 
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Table 2. No Difference In Costs Between CyA and 
FK 506 Cases 
Intensive care unit days 
Intensive care unit laboratory 
Operating room charges 
Variabfes 
liver acquisition charges 
Chemistry minus CyA level costs 
RESULTS 
Electrocardiogram 
Immunopathology 
Respiratory therapy 
Intravenous solutions 
The 20 subjects in each group consisted of8 women and 12 
men with a wide variety of chronic liver disease. including 
chronic cholestatic diseases such as :\Iagille's syndrome. 
primary biliary cirrhosis. and primary sclerosing cholangi-
tis, and a wide variety of chronic hepatocellular diseases 
including both alcoholic and viral liver disease. In addi-
tion. a case of Caroli's disease and a case with the 
Budd-Chiari syndrome were present in each group. The 
two groups were similar in age (FK 506 group. 40.2 ~ 2.5 
years: CyA group. 40.1 ~ 2.6 years) and had an identical 
mean UNOS score of 2.5 ~ 0.2 (Table I). 
No differences in costs between those treated with FK 
506 and Cy A were noted for nine variables (Table 2). 
These factors include the direct costs of organ procure-
ment. total operating room charges. and the duration and 
intensity of the immediate posttransplantation intensive 
care provided each. 
For two variables. the costs were increased in those 
receiving FK 506 compared with Cy:\ (Table 3). These 
included the costs accrued as a result of the serial liver 
biopsies obtained to monitor the postoperative course of 
the patients recel\ing FK 506 and the nuclear scans used to 
assess the effect of FK 506 on renal blood flow and various 
other renal functional assessments. :\s a fraction of the 
total charges. however. neither of these two costs ac-
counted for much. either in terms oi total cost dollars or in 
the difference in CO~h between the 1\\ 0 group,. 
The major taClL)r accounting f'..1r the difference in total 
costs between these t\\O group, 01 ratJcnh \\a~ the dura-
tion of hospitalization follo\\lng tran,rlantation and the 
charges relating to this lime inten al. in.:luding the dail) 
bed and pharm,I'::- charge~. \\ hl.:h are ,hlmn in T dble ~. 
Patients receiving CyA tended to .,ta~ In the hl),pltal 
almll.,t t\\ice as long IP < (J.()~I and accrued total bed 
charges almo.,t three times as great (p < O.()~l. Morcover. 
as a direct re~ult of a longer hospital ~tay. total pharmacy 
charges \\ere increased almost ti\efold IP < 0.0(07) and 
Table 3. Increased Costs Related to the Use of FK 506 
CyA 
AnatomiC pathoiogy protOCOl biopSies 
51681 :: 262 
Nuclear med,cme renal scans 
5460 :: 218 
p. 0005 
FK 506 
52391 :- 228 
52,068::: 288 
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Table 4. Reduced Costs Associated With the Use of FK 506 
Non-intenSive care unit days (P < 0.01) 
eyA 23.6 :: 35 d 
FK 506 13.2 ::: 1.3 d 
Total days (P < 0.02) 
CyA 35.9 :: 5.2 d 
FK 506 16.1 :: 1.3 d 
Bed charges (P < 0.02) 
CyA $33.121 :!: 8.387 
FK 506 $10,552:!: 1.340 
Pharmacy charges (P < 0.0007) 
eyA $19.842 :!: 3.381 
FK 506 $ 4,847 :: 1.371 
Pharmacy minus CyA charges (P < 0.002) 
CyA $17,051 :: 3,087 
FK 506 $ 4.847 :: 1.371 
Total charges (P < 0.04) 
CyA $244.863 ::: 45.501 
FK 506 $134.169:: 10.305 
were increased independent of the cost of CyA. When the 
costs for CyA were deleted from the total pharmacy 
charges. the pharmacy costs were still threefold greater (p 
< O.OO~ I for the patients receiving CyA compared with 
those receiving FK 506. 
A direct extension of the costs accrued a.., a conse-
quence (If the duration of hospitalizatIOn. \\ hateveT its 
reason5. was the costs of various laboraton scrvices 
pro\ideJ each group of patients. Table ~ sho\\ ~ that the 
COSh fc'r hematlliogy. cliOical chemlstn. mlcrobll1!c>g\. the 
Table 5. Reduced Charges Associated With the Use of FK 506 
:~emlstr) IP, 0005) 
CyA 524.482 :: 4611 
FK 5e6 514 026:: 1806 
:",err's~-, mln1"S C..,A -conl\Orlng Charges PC' 3 
CyA 521249:: 4171 
FK Se6 514.026 :: 1807 
o-ie"1a:: :gy r p. 000051 
CyA 57.739 :: 1019 
FK 5:::6 54.219:- 304 
\o\icrot J:ogy (P, 0041 
CyA 55. 145 :: 1.096 
FK 506 52.533:: 418 
8100c cank (p" 004) 
CyA 526.205 :: 5.300 
FK ;:)6513.467:: 2.020 
Dlalys,s (p < 004) 
CyA $2.032 ::: 924 
FK 506 0 
